No Gains in Long-term Survival after Liver Transplantation over the Past Three Decades

Abbas Rana, Ruth L. Ackah, Gwilym J. Webb, Karim J. Halazun, John M. Vierling, Hao Liu, Meng Fen Wu, Dor Yoeli, Michael Kueht, Ayse L. Mindikoglu, Norman L. Sussman, Nhu T. Galván, Ronald T. Cotton, Christine A. O'Mahony, John A. Goss

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: The aim of this study was to assess improvements in long-term survival after liver transplant by analyzing outcomes in transplant recipients who survived beyond 1 year. Summary of Background Data: Gains in short-term survival following liver transplantation have been gratifying. One-year survival in 1986 was 66% improved to over 92% in 2015. However, little is known about why long-term has not seen similar success. Methods: We analyzed 111,568 recipients from 1987 to 2016 using the Kaplan-Meier method for time-to-event analysis and multivariable Cox regression. Results: There were no significant gains in unadjusted long-term outcomes among 1-year survivors over the past 30 years. Only the time periods of 1987 to 1990 [hazard ratio (HR) 1.35, confidence interval CI) 1.28-1.42] and 1991 to 1995 (HR 1.17, CI 1.13-1.21) had a minor increase in risk compared with the period 2011 to 2016. Cause of death analysis suggests malignancy after transplantation is a growing problem and preventing recurrent hepatitis C with direct-acting antivirals (DDAs) may only have a limited impact. Furthermore, rejection leading to graft failure and death had a rare occurrence (1.7% of long-term deaths) especially when compared with the sequelae of long-term immunosuppression: malignancy (16.4%), nonrejection graft failure (9.8%), and infection (10.5%) (P < 0.001). Conclusion: In stark contrast to short-term survival, there have been no appreciable improvements in long-term survival following liver transplantation among 1-year survivors. Long-term sequelae of immunosuppression, including malignancy and infection, are the most common causes of death. This study highlights the need for better long-term immunosuppression management.

Original languageEnglish (US)
Pages (from-to)20-27
Number of pages8
JournalAnnals of surgery
Volume269
Issue number1
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Liver Transplantation
Survival
Immunosuppression
Transplants
Survivors
Cause of Death
Neoplasms
Hepatitis C
Infection
Antiviral Agents
Transplantation
Confidence Intervals
Liver

Keywords

  • chronic rejection
  • immunosuppression
  • liver transplantation
  • long-term survival

ASJC Scopus subject areas

  • Surgery

Cite this

Rana, A., Ackah, R. L., Webb, G. J., Halazun, K. J., Vierling, J. M., Liu, H., ... Goss, J. A. (2019). No Gains in Long-term Survival after Liver Transplantation over the Past Three Decades. Annals of surgery, 269(1), 20-27. https://doi.org/10.1097/SLA.0000000000002650

No Gains in Long-term Survival after Liver Transplantation over the Past Three Decades. / Rana, Abbas; Ackah, Ruth L.; Webb, Gwilym J.; Halazun, Karim J.; Vierling, John M.; Liu, Hao; Wu, Meng Fen; Yoeli, Dor; Kueht, Michael; Mindikoglu, Ayse L.; Sussman, Norman L.; Galván, Nhu T.; Cotton, Ronald T.; O'Mahony, Christine A.; Goss, John A.

In: Annals of surgery, Vol. 269, No. 1, 01.01.2019, p. 20-27.

Research output: Contribution to journalArticle

Rana, A, Ackah, RL, Webb, GJ, Halazun, KJ, Vierling, JM, Liu, H, Wu, MF, Yoeli, D, Kueht, M, Mindikoglu, AL, Sussman, NL, Galván, NT, Cotton, RT, O'Mahony, CA & Goss, JA 2019, 'No Gains in Long-term Survival after Liver Transplantation over the Past Three Decades', Annals of surgery, vol. 269, no. 1, pp. 20-27. https://doi.org/10.1097/SLA.0000000000002650
Rana, Abbas ; Ackah, Ruth L. ; Webb, Gwilym J. ; Halazun, Karim J. ; Vierling, John M. ; Liu, Hao ; Wu, Meng Fen ; Yoeli, Dor ; Kueht, Michael ; Mindikoglu, Ayse L. ; Sussman, Norman L. ; Galván, Nhu T. ; Cotton, Ronald T. ; O'Mahony, Christine A. ; Goss, John A. / No Gains in Long-term Survival after Liver Transplantation over the Past Three Decades. In: Annals of surgery. 2019 ; Vol. 269, No. 1. pp. 20-27.
@article{b0564366dc654978b7344281b76cb8d4,
title = "No Gains in Long-term Survival after Liver Transplantation over the Past Three Decades",
abstract = "Objective: The aim of this study was to assess improvements in long-term survival after liver transplant by analyzing outcomes in transplant recipients who survived beyond 1 year. Summary of Background Data: Gains in short-term survival following liver transplantation have been gratifying. One-year survival in 1986 was 66{\%} improved to over 92{\%} in 2015. However, little is known about why long-term has not seen similar success. Methods: We analyzed 111,568 recipients from 1987 to 2016 using the Kaplan-Meier method for time-to-event analysis and multivariable Cox regression. Results: There were no significant gains in unadjusted long-term outcomes among 1-year survivors over the past 30 years. Only the time periods of 1987 to 1990 [hazard ratio (HR) 1.35, confidence interval CI) 1.28-1.42] and 1991 to 1995 (HR 1.17, CI 1.13-1.21) had a minor increase in risk compared with the period 2011 to 2016. Cause of death analysis suggests malignancy after transplantation is a growing problem and preventing recurrent hepatitis C with direct-acting antivirals (DDAs) may only have a limited impact. Furthermore, rejection leading to graft failure and death had a rare occurrence (1.7{\%} of long-term deaths) especially when compared with the sequelae of long-term immunosuppression: malignancy (16.4{\%}), nonrejection graft failure (9.8{\%}), and infection (10.5{\%}) (P < 0.001). Conclusion: In stark contrast to short-term survival, there have been no appreciable improvements in long-term survival following liver transplantation among 1-year survivors. Long-term sequelae of immunosuppression, including malignancy and infection, are the most common causes of death. This study highlights the need for better long-term immunosuppression management.",
keywords = "chronic rejection, immunosuppression, liver transplantation, long-term survival",
author = "Abbas Rana and Ackah, {Ruth L.} and Webb, {Gwilym J.} and Halazun, {Karim J.} and Vierling, {John M.} and Hao Liu and Wu, {Meng Fen} and Dor Yoeli and Michael Kueht and Mindikoglu, {Ayse L.} and Sussman, {Norman L.} and Galv{\'a}n, {Nhu T.} and Cotton, {Ronald T.} and O'Mahony, {Christine A.} and Goss, {John A.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/SLA.0000000000002650",
language = "English (US)",
volume = "269",
pages = "20--27",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - No Gains in Long-term Survival after Liver Transplantation over the Past Three Decades

AU - Rana, Abbas

AU - Ackah, Ruth L.

AU - Webb, Gwilym J.

AU - Halazun, Karim J.

AU - Vierling, John M.

AU - Liu, Hao

AU - Wu, Meng Fen

AU - Yoeli, Dor

AU - Kueht, Michael

AU - Mindikoglu, Ayse L.

AU - Sussman, Norman L.

AU - Galván, Nhu T.

AU - Cotton, Ronald T.

AU - O'Mahony, Christine A.

AU - Goss, John A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: The aim of this study was to assess improvements in long-term survival after liver transplant by analyzing outcomes in transplant recipients who survived beyond 1 year. Summary of Background Data: Gains in short-term survival following liver transplantation have been gratifying. One-year survival in 1986 was 66% improved to over 92% in 2015. However, little is known about why long-term has not seen similar success. Methods: We analyzed 111,568 recipients from 1987 to 2016 using the Kaplan-Meier method for time-to-event analysis and multivariable Cox regression. Results: There were no significant gains in unadjusted long-term outcomes among 1-year survivors over the past 30 years. Only the time periods of 1987 to 1990 [hazard ratio (HR) 1.35, confidence interval CI) 1.28-1.42] and 1991 to 1995 (HR 1.17, CI 1.13-1.21) had a minor increase in risk compared with the period 2011 to 2016. Cause of death analysis suggests malignancy after transplantation is a growing problem and preventing recurrent hepatitis C with direct-acting antivirals (DDAs) may only have a limited impact. Furthermore, rejection leading to graft failure and death had a rare occurrence (1.7% of long-term deaths) especially when compared with the sequelae of long-term immunosuppression: malignancy (16.4%), nonrejection graft failure (9.8%), and infection (10.5%) (P < 0.001). Conclusion: In stark contrast to short-term survival, there have been no appreciable improvements in long-term survival following liver transplantation among 1-year survivors. Long-term sequelae of immunosuppression, including malignancy and infection, are the most common causes of death. This study highlights the need for better long-term immunosuppression management.

AB - Objective: The aim of this study was to assess improvements in long-term survival after liver transplant by analyzing outcomes in transplant recipients who survived beyond 1 year. Summary of Background Data: Gains in short-term survival following liver transplantation have been gratifying. One-year survival in 1986 was 66% improved to over 92% in 2015. However, little is known about why long-term has not seen similar success. Methods: We analyzed 111,568 recipients from 1987 to 2016 using the Kaplan-Meier method for time-to-event analysis and multivariable Cox regression. Results: There were no significant gains in unadjusted long-term outcomes among 1-year survivors over the past 30 years. Only the time periods of 1987 to 1990 [hazard ratio (HR) 1.35, confidence interval CI) 1.28-1.42] and 1991 to 1995 (HR 1.17, CI 1.13-1.21) had a minor increase in risk compared with the period 2011 to 2016. Cause of death analysis suggests malignancy after transplantation is a growing problem and preventing recurrent hepatitis C with direct-acting antivirals (DDAs) may only have a limited impact. Furthermore, rejection leading to graft failure and death had a rare occurrence (1.7% of long-term deaths) especially when compared with the sequelae of long-term immunosuppression: malignancy (16.4%), nonrejection graft failure (9.8%), and infection (10.5%) (P < 0.001). Conclusion: In stark contrast to short-term survival, there have been no appreciable improvements in long-term survival following liver transplantation among 1-year survivors. Long-term sequelae of immunosuppression, including malignancy and infection, are the most common causes of death. This study highlights the need for better long-term immunosuppression management.

KW - chronic rejection

KW - immunosuppression

KW - liver transplantation

KW - long-term survival

UR - http://www.scopus.com/inward/record.url?scp=85058882783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058882783&partnerID=8YFLogxK

U2 - 10.1097/SLA.0000000000002650

DO - 10.1097/SLA.0000000000002650

M3 - Article

VL - 269

SP - 20

EP - 27

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 1

ER -